Metabolic & GLP-1Evidence B3 cited

Pemvidutide

aka ALT-801 · dual GLP-1/glucagon agonist

Dual GLP-1/glucagon receptor agonist. MASH Phase 2 data in The Lancet.

Sequence

One-letter27 residues

HXQGTFTSDYSKYLDEKAAKEFIQWLLQT

Read this before quoting the sequence

29-residue GLP-1/glucagon (1:1) dual receptor agonist, also known as ALT-801. Sequence as recorded in ChEMBL (CHEMBL5095142). 'X' at position 2 is a non-standard residue that the ChEMBL record does not resolve. The same record lists a bridge between residues 16 and 20; neither of those residues is cysteine, so this is a side-chain (lactam-type) bridge rather than a disulfide despite ChEMBL's field label. Pemvidutide additionally carries Altimmune's EuPort lipid/albumin-binding domain, which is not represented in the one-letter string.

Source ↗

Mechanism of action

Dual GLP-1 and glucagon receptor agonist (ALT-801) with EuPort lipid modification for once-weekly dosing. Targets body weight and hepatic steatosis (studied in MASH/obesity).

What the evidence actually shows

Grade B

Phase 2b IMPACT trial published Lancet 2025. Phase 3 underway.

Regulatory status

Status

Investigational; not approved by FDA or EMA.

Clinical stage

Phase 2b is the most advanced stage reached. ClinicalTrials.gov lists 7 studies (4 completed Phase 1, 2 completed Phase 2, 1 recruiting Phase 2); the IMPACT Phase 2b MASH trial (NCT05989711) reported 24-week results in 2025. No Phase 3 study registered.

Source ↗

Dosing — what backs each figure

Pemvidutide (ALT-801) is an investigational GLP-1/glucagon dual agonist with no approved label anywhere; published human dosing is once-weekly subcutaneous 1.2-2.4 mg in phase 1b/2a MASLD and phase 2b MASH trials. It is not approved for any indication and there is no established maintenance or 'cycle' regimen.

ClinicalApproved labelling or a published human trial

1.2 mg, 1.8 mg or 2.4 mg subcutaneously once weekly for 12 weeks (no titration reported)
adults with MASLD, BMI >=28 and liver fat content >=10% (n=94) · subcutaneous
Harrison et al., J Hepatol 2025;82(1):7-17, phase 1b/2a (NCT05006885) ↗
1.2 mg or 1.8 mg subcutaneously once weekly, administered without dose titration, assessed at 24 weeks within an ongoing 48-week trial
adults with biopsy-confirmed MASH and fibrosis stage F2-F3 (n=212) · subcutaneous
IMPACT phase 2b, Lancet 2025 Dec 6 (NCT05989711) ↗

Handling and storage

No compound-specific stability data exists

No compound-specific stability data from an approved label or peer-reviewed stability study was located. Only generic research-peptide handling guidance exists, which is not compound-specific and is therefore not recorded here. Pemvidutide is investigational and has no approved label. General peptide handling still applies — reconstitute gently, keep it cold, keep it dark — but any specific figure you see quoted for this compound elsewhere is someone's assumption, not a measurement.

→ Reconstitution walkthrough → Reconstitution calculator

Safety

References (3)

Noureddin M, Harrison SA, Loomba R, Alkhouri N, Chalasani N, et al. (2025) Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. ↗
The LancetPMID 41237796DOI
IMPACT Phase 2b trial (NCT05989711), 212 patients with biopsy-confirmed MASH and F2/F3 fibrosis. Once-weekly subcutaneous pemvidutide 1.2 mg or 1.8 mg without dose titration achieved MASH resolution without fibrosis worsening in 58% and 52% of patients respectively versus 20% on placebo (both p<0.0001); fibrosis improvement did not reach significance.
Harrison SA, Browne SK, Suschak JJ, Tomah S, Gutierrez JA, Yang J, Roberts MS, Harris MS (2025) Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. ↗
Journal of HepatologyPMID 39002641DOI
Randomised placebo-controlled trial (NCT05006885), 94 patients with MASLD; subcutaneous pemvidutide 1.2, 1.8 or 2.4 mg once weekly for 12 weeks reduced liver fat content by 46.6%, 68.5% and 57.1% respectively versus 4.4% for placebo, with maximal weight loss of -4.3% at the 1.8 mg dose.
Browne SK, Suschak JJ, Tomah S, et al. (2025) Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. ↗
JHEP ReportsPMID 41113119DOI
24-week randomised controlled extension of pemvidutide dosing in MASLD, reporting liver fat, weight and tolerability outcomes.

Data provenance

Chemistry and citations on this page were checked against primary sources on 2026-08-14. Values that could not be verified were left blank rather than filled with a plausible guess.

Could not verify
molecularFormula, molecularWeight, casNumber, pubchemCid, storage, reconstitution, regulatory.wada, sequence.position2Residue

Research use only

This profile is educational reference material. It is not medical advice, not a prescription, and not an endorsement of self-administration. Compounds discussed here are research chemicals and most are not approved for human therapeutic use.

Related in Metabolic & GLP-1

5-Amino-1MQ

A small molecule researched for blocking NNMT enzyme to boost NAD+ levels and fat metabolism.

Amycretin

Dual amylin/GLP-1 receptor agonist from Novo Nordisk. Single molecule.

AOD-9604

A modified hGH fragment researched for targeted fat breakdown without altering blood sugar or IGF-1.